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Increased Risk in Patients With High
Platelet Aggregation Receiving Chronic Clopidogrel
Therapy Undergoing Percutaneous Coronary Intervention
Is the Current Antiplatelet Therapy Adequate?
Kevin P. Bliden, BS, Joseph DiChiara, BS, Udaya S. Tantry, PHD, Ashwani K. Bassi, MD,
Srivasavi K. Chaganti, MD, Paul A. Gurbel, MD
Baltimore, Maryland
Objectives We sought to determine whether patients receiving chronic clopidogrel therapy undergoing nonemergent stent-
ing who display high on-treatment preprocedural platelet aggregation measured by standard light transmittance
aggregometry and thrombelastography (TEG) will be at increased risk for poststenting ischemic events.
Background Patients exhibiting heightened platelet reactivity to adenosine diphosphate (ADP) might be at increased risk for
recurrent ischemic events after coronary stenting.
Methods A total of 100 consecutive patients receiving chronic antiplatelet therapy consisting of aspirin (325 mg qd) and
clopidogrel (75 mg qd) were studied before undergoing nonemergent stenting. Patients were followed for 1 year
after coronary stenting for the occurrence of death, myocardial infarction, stent thrombosis, stroke, or ischemia
requiring a hospital stay.
Results All patients were aspirin responsive. Patients with ischemic events (23 of 100, 23%) within 1 year had greater
on-treatment prestent ADP-induced platelet aggregation than patients without ischemic events by aggregometry
and TEG (p  0.001 for both measurements). Of patients with an ischemic event, 70% and 87% displayed high
on-treatment platelet reactivity at baseline by aggregometry and TEG, respectively. High on-treatment platelet
reactivity as measured by aggregometry and TEG were the only variables significantly related to ischemic events
(p  0.001 for both assays). The administration of eptifibatide reduced periprocedural elevation in platelet reac-
tivity, with no significant differences in bleeding events.
Conclusions Patients receiving chronic clopidogrel therapy undergoing nonemergent percutaneous coronary intervention who
exhibit high on-treatment ADP-induced platelet aggregation are at increased risk for postprocedural ischemic
events. These findings might have implications for the alteration in clopidogrel maintenance dose and use of
glycoprotein IIb/IIIa inhibitors in selected patients. (J Am Coll Cardiol 2007;49:657–66) © 2007 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.10.050l
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tlatelet aggregation is a central process in the development
f ischemic complications after percutaneous coronary in-
ervention (PCI) (1–4). Dual antiplatelet therapy with
spirin and clopidogrel are the gold standard to attenuate
latelet function during PCI. However, despite the superior
rotection documented in clinical trials with dual antiplate-
rom the Sinai Center for Thrombosis Research, Baltimore, Maryland. This study
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tudy the physical properties of clot formation with respect to recurrent ischemic
vents postelective stenting; research funding from Schering and Millennium to study
ntiplatelet effects of clopidogrel and eptifibatide in elective stenting; and research
rant funding from Bayer to study the antiplatelet effects of aspirin in outpatients.w
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006, accepted October 1, 2006.et therapy, it has been demonstrated that nearly 20% of
atients undergoing PCI will experience recurrent ischemic
r thrombotic events (5). It has been repeatedly shown that
significant percentage of patients display no demonstrable
ntiplatelet effect by ex vivo measurements after a 300-mg
lopidogrel loading dose (6,7). It has been hypothesized that
atients exhibiting clopidogrel nonresponsiveness and
eightened platelet reactivity to adenosine diphosphate
ADP) are inadequately protected and might be at increased
isk for recurrent events (6,8).
A relationship between clopidogrel nonresponsiveness and
ost-PCI ischemic events in clopidogrel-naïve patients has
een recently suggested (5,9–11). Clinical studies indicated
hat postprocedural heightened platelet reactivity is associated
ith increased myocardial necrosis and inflammation marker
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creased post-treatment platelet re-
activity has been associated with
recurrent ischemic events and stent
thrombosis (4,5,11). These studies
emphasize the potentially sizeable
risks associated with inadequate
platelet inhibition from current
antiplatelet therapy.
Among patients receiving main-
tenance dose clopidogrel therapy, a
certain percentage display height-
ened platelet reactivity to ADP
(4,6,13). Despite this evidence,
there is no established recom-
mendation for clopidogrel loading
n patients receiving chronic clopidogrel therapy undergoing PCI.
urthermore, there are no sufficient data correlating heightened
latelet reactivity with adverse cardiovascular events in these
atients. The goal of the present study was to quantify this
elationship. We hypothesized that patients receiving chronic
lopidogrel therapy undergoing non-emergent PCI who display
igh preprocedural platelet reactivity, as measured by standard
ight transmittance aggregometry (LTA) and thrombelastography
TEG), are at increased risk for post-PCI ischemic events.
ethods
his study was approved by the investigational review
oard. One hundred consecutive patients receiving clopi-
ogrel therapy (75 mg qd) for1 month before undergoing
on-emergent coronary stenting were enrolled after giving
nformed consent. A clopidogrel loading dose was not
dministered. All patients had received at least 81 mg
spirin for 7 days before the procedure. Patients were 18
ears old. The exclusion criteria were: a history of bleeding
iathesis, acute myocardial infarction within 48 h, elevated
ardiac markers (above upper limits normal for the respec-
ive assay), cerebrovascular event within 3 months, illicit
rug or alcohol abuse, prothrombin time 1.5 times con-
rol, platelet count 100,000/mm3, hematocrit 30%,
reatinine 4.0 mg/dl, and glycoprotein (GP) IIb/IIIa use
efore the procedure.
On the day of the procedure and daily thereafter, 325 mg
spirin was administered. Eptifibatide was administered at
he discretion of the treating physician with the ESPRIT
Evaluation of Subcutaneous Proleukin in a Randomized
nternational Trial) study protocol as a double bolus (180
g/kg) followed by an infusion (2 g/kg/min) for 18 to 24 h
fter procedure. Unfractionated heparin was administered
ccording to the ESPRIT dosing regimen (60 U/kg) as a
olus to all patients in the catheterization laboratory imme-
iately before stenting (14). Clopidogrel was prescribed in
ll patients for at least 6 months after procedure.
lood sampling. Baseline blood samples were obtained
Abbreviations
and Acronyms
AA  arachidonic acid
ADP  adenosine diphosphate
GP  glycoprotein
HPR  high on-treatment
platelet reactivity
LTA  light transmittance
aggregometry
NPR  normal on-treatment
platelet reactivity
PCI  percutaneous
coronary intervention
TEG  thrombelastograph(y)rom patients in a fasting state in the catheterization caboratory through the indwelling femoral vessel sheath.
amples were transferred to separate vacutainer blood col-
ecting tubes (Becton-Dickinson, Franklin Lakes, New Jersey)
ontaining 3.8% trisodium citrate or lithium heparin. After
iscarding the first 2 to 3 ml of free flowing blood, the
acutainer tubes were filled to capacity and gently inverted 3 to
times to ensure complete mixing of the anticoagulant.
aseline samples were obtained before coronary intervention
nd at 3 h and 18 to 24 h after stenting. In patients treated with
ptifibatide, the 18 to 24 h blood draw was performed within
h after completion of the eptifibatide infusion.
latelet aggregation. The blood-citrate tubes were centri-
uged at 120 g for 5 min to recover platelet rich plasma
PRP) and further centrifuged at 850 g for 10 min to recover
latelet poor plasma (PPP). The PRP and PPP were stored
t room temperature to be used within 2 h. Platelet
ggregation was assessed as described previously (3). Briefly,
latelets were stimulated with 5 mol/l ADP and 1 mmol/l
rachidonic acid (AA). Aggregation was assessed with a
hronolog Lumi-Aggregometer (Model 490-4D) with the
ggrolink software package (Chronolog, Havertown, Penn-
ylvania). Aggregation was expressed as the maximum
ercent change in light transmittance from baseline, with
PP as a reference.
hrombelastograph Hemostasis Analyzer With Platelet-
apping. The Food and Drug Administration-approved
hrombelastograph Hemostasis Analyzer With Platelet-
apping assay (Haemoscope Corp., Niles, Illinois) relies on
he measurement of thrombin-induced clot strength to
nable a quantitative analysis of platelet function (15,16).
he assay uses heparin as an anticoagulant to eliminate
hrombin activity in the sample. Reptilase and factor XIIIa
activator F) are used to generate a cross-linked fibrin clot to
solate the fibrin contribution to clot strength (17). The
ontribution of P2Y12 receptor or cyclooxygenase pathways
o the clot formation can be measured by the addition of the
ppropriate agonist, ADP or AA.
Blood was analyzed according to the manufacturer’s
nstructions. One milliliter heparinized blood was trans-
erred to a vial containing kaolin and mixed by inversion.
ive hundred microliters of the activated blood were then
ransferred to a vial containing heparinase and mixed to
eutralize heparin. The neutralized blood (360 l) was
mmediately added to a heparinase-coated cup and assayed
n the TEG analyzer to measure the thrombin-induced clot
trength (MAthrombin). Heparinized blood (340 l) was
dded to a noncoated cup containing reptilase and activator
to generate a whole blood crosslinked clot in the absence
f thrombin generation or platelet stimulation (MAfibrin). A
hird sample (340 l) of heparinized blood was added to a
onheparinase-coated cup in the presence of the activator F
nd ADP (2 mol) or AA (1 mmol/l) to generate a whole
lood-crosslinked clot with platelet activation (MAADP or
AAA). Platelet aggregation in response to ADP or AA isalculated with computerized software on the basis of the
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MAthrombin  MAfibrin)]  100 (Fig. 1).
efinitions and clinical outcomes. HIGH ON-TREATMENT
LATELET REACTIVITY. The cut points for high on-
reatment platelet reactivity (HPR) were defined as 50%
DP-induced platelet aggregation after stimulation with
-mol ADP at baseline as measured by LTA or 70%
DP-induced aggregation with 2-mol ADP at baseline as
easured by TEG (17). All patients below these cut points
ere defined as exhibiting normal on-treatment platelet
eactivity (NPR). All tables are representative of 5 mol/l
DP-induced LTA aggregation values.
SPIRIN RESISTANCE. Aspirin resistance was defined as
20% platelet aggregation after stimulation by 1-mmol/l
A as measured by LTA or more than 50% platelet
ggregation after stimulation by 1-mmol/l AA as measured
y TEG (18).
LINICAL OUTCOMES. Patients were contacted by tele-
hone at 1, 6, and 12 months to identify the occurrence of
dverse events. Patient records including electronic source
ocuments were obtained and reviewed by 2 physicians
linded to the study who adjudicated events. Ischemic
vents were defined as: death secondary to any cardiovascu-
ar cause, stroke, myocardial infarction (in-hospital and after
ischarge), ischemia requiring a hospital stay, and target
essel revascularization (TVR), nontarget vessel revascular-
zation (NTVR), or medical management. Myocardial in-
arction was defined as the occurrence of ischemic symp-
oms and a troponin-I value upper limits of normal (1.5
g/ml). Unstable angina was defined as the occurrence of
schemic symptoms requiring a hospital stay. Bleeding was
Figure 1 Thrombelastograph PlateletMapping Analysis Parame
MAThrombin  measure of maximum thrombin-induced platelet-fibrin clot strength; M
MAADP or AA  represents clot strength after adenosine diphosphate (ADP) or aracuantified according to the Thrombolysis In Myocardial wnfarction (TIMI) criteria (19). In brief, minor bleeding was
efined as clinically overt bleeding accompanied by a fall in
emoglobin of 3.0 to 5.0 g/dl or a fall in hematocrit of 9%
o 15%. Major bleeding occurred when the hemoglobin
ecreased 5 g/dl or the hematocrit decreased 15%.
tatistical analysis. Categorical variables are expressed as n
%), and continuous variables are expressed as mean  SD
ith p  0.05 considered statistically significant. The Fischer
xact test and Mann-Whitney Rank Sum test were used for
omparison of categorical and continuous variables between
latelet reactivity groups. Multivariate Cox regression analysis
as used to evaluate the significance of the following variables
oncerning ischemic events within 1 year of follow-up: HPR
measured by TEG and LTA), age, history of diabetes, history
f hypertension, smoking (current), bare-metal stent (BMS)
ersus drug-eluting stent (DES), and patients presenting post-
cute coronary syndrome. Pearson product moment correlation
as used to measure the correlation between LTA and TEG
ssays. All statistical calculations for the aforementioned anal-
ses were performed with SigmaStat software (Point Rich-
ond, California). A receiver operator curve (ROC) analysis
as used to determine the ability of LTA and TEG to predict
schemic events. This analysis was performed with MedCalc
oftware (Mariakerke, Belgium).
etermination of sample size. It has been demonstrated
hat approximately 20% of patients with a history of prior
oronary revascularization undergoing repeat PCI will experi-
nce a recurrent ischemic event within 1 year of repeat coronary
ntervention (20). We have previously demonstrated that
atients in the upper quartile of platelet reactivity are at
pproximately 3 times greater risk for repeat ischemic events
17). Therefore, we hypothesized that 30% and 10% of patients
 contribution of fibrin to clot strength;
c acid (AA) stimulation.ters
AFibrin
hidoniith HPR and NPR in the current study will experience a
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alculation from SigmaStat software, it is estimated that the
ample size required for 95% power with the alpha of 0.05 is
pproximately 100 patients.
esults
atients. One hundred patients receiving chronic clopi-
ogrel (1 month) and aspirin therapy were enrolled.
mong these patients, 12 were admitted with myocardial
nfarction (enrolled 48 h after infarction) and 13 had
nstable angina. The remainder of the patients had stable
ngina, and the procedures were nonemergent. A total of 30
atients received treatment with GP IIb/IIIa inhibitors at
Patient Demographics
Table 1 Patient Demographics
Total Grou
(n  100
Age (yrs) 66 11
Gender and ethnicity, n (%)
Caucasian male 60 (60)
Caucasian female 17 (17)
African-American male 12 (12)
African-American female 11 (11)
BMI (kg/m2) 30 6
Systolic BP (mm Hg) 145 22
Diastolic BP (mm Hg) 76 16
Subject presentation, n (%)
Elective 75 (75)
Unstable angina 13 (13)
Myocardial infarction 12 (12)
Risk factors/medical history, n (%)
Smoking 56 (56)
Family history of CAD 53 (53)
Hypertension 74 (74)
Hyperlipidemia 83 (83)
Diabetes 44 (44)
Renal disease 12 (12)
Peripheral vascular disease 13 (13)
Prior myocardial infarction 40 (40)
Prior CABG 31 (31)
Prior PTCA 49 (49)
Prior CVA 15 (15)
Baseline medications, n (%)
Beta-blockers 84 (84)
ACE inhibitors 71 (71)
Calcium-channel blockers 26 (26)
Lipid-lowering agents
3A4 pathway metabolized 74 (74)
Non-3A4 pathway metabolized 14 (14)
Laboratory data
WBC ( 1,000/mm3) 7.4 2.
Platelets ( 1,000/mm3) 233 75
Hemoglobin (g/dl) 13.2 2
Hematocrit (%) 40 5
Creatinine (g/dl) 1.1 0.
ACE angiotensin-converting enzyme; BMI body mass index; BP b
artery disease; CVA  cerebrovascular accident; HPR  high on-treatment pla
not significant; PTCA  percutaneous transluminal coronary angioplasty; WBhe discretion of the physician. Serial platelet assays were
ompleted for all subjects.
emographics. Patient demographics and procedural
haracteristics are shown in Tables 1 and 2, respectively.
riefly, cardiovascular risk factors and multivessel interven-
ions using drug-eluting stents were common. No signifi-
ant differences in age, gender, ethnicity, body mass index,
aseline medications or hematological data existed between
eactivity groups. Patients with HPR exhibited a higher
revalence of hypertension, diabetes, and use of calcium-
hannel blockers.
latelet aggregation. All patients were aspirin responsive.
ean preprocedural ADP-induced platelet aggregation was
HPR Group
(n  22)
NPR Group
(n  78)
HPR vs. NPR
p Value
67 10 66 11 NS
13 (59) 47 (60) NS
4 (18) 13 (17) NS
1 (5) 11 (14) NS
4 (18) 7 (9) NS
31 7 30 6 NS
154 19 143 23 0.04
77 15 76 17 NS
18 (82) 57 (73) NS
2 (9) 11 (14) NS
2 (9) 10 (13) NS
14 (64) 42 (54) NS
13 (59) 40 (51) NS
19 (86) 55 (71) 0.07
19 (86) 64 (82) NS
14 (64) 30 (38) 0.01
3 (14) 9 (12) NS
3 (14) 10 (13) NS
6 (27) 34 (44) NS
9 (41) 22 (28) NS
13 (64) 36 (46) 0.07
3 (14) 12 (15) NS
18 (82) 66 (85) NS
14 (64) 57 (73) NS
9 (41) 17 (22) 0.04
18 (82) 56 (72) NS
1 (5) 13 (17) NS
7.4 2.7 7.4 1.9 NS
236 86 231 71 NS
13.1 2 13.3 2 NS
39.5 5 40.0 5 NS
1.0 0.3 1.1 0.4 NS
essure; CABG coronary artery bypass graft surgery; CAD coronaryp
)
2
4
lood pr
telet reactivity; NPR  normal on-treatment platelet reactivity; NS 
C  white blood cells.
3
b
s
p
3

s
0
I
f
p
w
N
i
u
m
d
r
i
d
e
R
e
o
b
T
i
1
b
t
o
d
t
a
c
t

f
right co
Ma
A
o
t
661JACC Vol. 49, No. 6, 2007 Bliden et al.
February 13, 2007:657–66 Chronic Clopidogrel Therapy and Ischemic Risk8  16% as measured by LTA and 55  21% as measured
y TEG (Table 3). Baseline on-treatment aggregation was
ignificantly higher in patients with ischemic events than in
atients without events as measured by LTA (50  13% vs.
1 13% respectively, p 0.0001) (Fig. 2A) and TEG (76
13% vs. 49  13% respectively, p  0.0001) (Fig. 2B). A
trong correlation was shown between these assays (p 
.0001, r  0.82) (Fig. 3).
schemic events. One-year follow-up data were completed
or all patients. A total of 26 ischemic events occurred in 23
atients (23%) within 1 year of discharge (Table 4). There
ere no strokes or in-hospital deaths. One patient in the
PR group (presenting with unstable angina) and 2 patients
Procedural Characteristics
Table 2 Procedural Characteristics
Total Group
(n  100)
Length of procedure (min) 62 28
Ejection fraction (%) 50 11
Number of vessels treated 1.2 0.4
Number of lesions treated 1.4 0.6
Lesion morphology
De novo, n (%) 89 (89)
Bifurcation lesions 5 (5)
Calcified lesions 17 (17)
Thrombus present 4 (4)
Total occlusion 10 (10)
Dissection 1 (1)
Lesion location, n (%)
LAD 38 (38)
CX 32 (32)
RCA 34 (34)
SVG 11 (11)
Stent types, n (%)
Drug-eluting 75 (75)
Bare-metal 24 (24)
PTCA only 1 (1)
Reference vessel diameter (mm) 3.0 0.5
Total lesion length (mm) 22.1 16
Prestenosis (%) 88 5
Poststenosis (%) 4 2
Procedural success, n (%) 97 (97)
CX  circumflex artery; LAD  left anterior descending artery; RCA 
Table 1.
ean Platelet Aggregationnd Percentage of Patients With HPR
Table 3 Mean Platelet Aggregationand Percentage of Patients With HPR
Platelet Assay Baseline 95% CI
HPR
(% of Patients)
LTA-5 mol/l ADP (%) 38/ 16 (34–40) 22
TEG-MAADP (%) 55/ 21 (50–59) 30
Aspirin Resistance
(% of Patients)
LTA-1 mmol/l AA (%) 2 2 (0–4) 0
TEG-MAAA (%) 2 2 (0–4) 0
A  arachidonic acid; ADP  adenosine diphosphate; CI  confidence interval; HPR  highe
n-treatment platelet reactivity; LTA  light transmittance aggregometry; NPR  normal on-
reatment platelet reactivity; TEG  thrombelastography.n the HPR group (1 presenting with unstable angina and 1
ndergoing non-emergent PCI) suffered periprocedural
yocardial infarctions, and 2 patients in the HPR group
eveloped subacute stent thrombosis within 1 week of
evascularization. Of the 23 patients (30%), 7 suffered
schemic events after completion of their prescribed clopi-
ogrel treatment. The mean time from discharge to initial
vent occurrence was 147  106 days (Fig. 4).
elation of HPR to events. Of patients with an ischemic
vent, 70% displayed HPR at baseline, whereas only 8%
f patients without an ischemic event displayed HPR at
aseline as measured by LTA (Fig. 2A). Similarly, the
EG assay demonstrated that 87% of patients with an
schemic event displayed baseline HPR, whereas only
7% of patients without an ischemic event displayed
aseline HPR (Fig. 2B). This resulted in positive predic-
ive values of 73% and 67% and negative predictive values
f 91% and 94% for the LTA and TEG, respectively,
emonstrating 87% test efficiency with the LTA and 85%
est efficiency with the TEG. By analyzing the area under
combined receiver-operating characteristic (ROC)
urve, LTA and TEG demonstrated the ability to dis-
inguish between ischemic and nonischemic groups (area
0.862, p  0.0001 for LTA; area  0.881, p  0.0001
or TEG) (Fig. 5). Within the total group, 16 patients
HPR Group
(n  22)
NPR Group
(n  78)
HPR vs. NPR
p Value
62 34 62 26 NS
50 12 50 10 NS
1.2 0.4 1.2 0.4 NS
1.6 0.7 1.3 0.6 NS
19 (86) 70 (90) NS
1 (5) 4 (5) NS
2 (9) 16 (20) NS
0 (0) 4 (5) NS
3 (14) 7 (9) NS
0 (0) 1 (1) NS
7 (32) 31 (40) NS
10 (45) 22 (28) NS
9 (41) 25 (32) NS
2 (9) 9 (12) NS
17 (77) 58 (75) NS
5 (23) 19 (24) NS
0 (0) 1 (1) NS
3.0 0.4 3.0 0.5 NS
26.0 24 21.0 13 NS
89 6 88 5 NS
5 3 4 2 NS
21 (95) 76 (97) NS
ronary artery; SVG  saphenous vein graft; other abbreviations as inxhibited concordant HPR as measured by both LTA
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(A) Graph demonstrating percentage of patients with and without ischemic events
sine diphosphate (ADP)-induced light transmittance aggregometry. Dashed line ind
without ischemic events displaying HPR as measured by 2-mol/l ADP-induced thr
Figure 3 Linear Regression Model Representing
the Correlation Between LTA and TEG
ADP  adenosine diphosphate; LTA  light transmittance aggregometry;
TEG  thrombelastograph.and TEG, 21 patients demonstrated discordant HPR by
ither LTA or TEG, and the remaining 63 patients
isplayed NPR as measured by both assays. Eighty-eight
ercent of patients with concordant HPR, 29% of pa-
ients with discordant HPR, and 5% of patients with
PR suffered ischemic events. Despite the higher prev-
lence of hypertension, diabetes, and use of calcium
hannel blockers in patients with HPR, analysis with
ultivariate Cox regression demonstrated no prognostic
ignificance between these risk factors and ischemic
vents. High on-treatment platelet reactivity as measured
y LTA and TEG were the only variables significantly
elated to ischemic events (p  0.001) (Table 5).
ffect of eptifibatide treatment on platelet reactivity and
schemic events. In patients not treated with eptifibatide,
here was an 18% relative increase in mean platelet
ggregation by LTA from baseline to 3 h after procedure
39  17% to 48  14%, p  0.0004) followed by a
eturn to preprocedural aggregation values by 18 to 24 h.
owever, an increase was not observed with the TEG
ying high on-treatment platelet reactivity (HPR) as measured by 5 mol/l adeno-
cut point for HPR. (B) Graph demonstrating percentage of patients with and
astography. Dashed line indicates cut point for HPR.displa
icates
ombelssay (56  21% to 55  24, p  0.793). In patients
t
m
3
r
t
t
m
i
r
p
p
5
e
c
c
e
t
e
r
0
o
a
(
D
T
c
w
i
A
a
e
1
2
m
t
w
v
a
t
s
p
n
e
o
p
t
p
i
a
r
t
p
e
s
I
H
663JACC Vol. 49, No. 6, 2007 Bliden et al.
February 13, 2007:657–66 Chronic Clopidogrel Therapy and Ischemic Riskreated with eptifibatide, a 97% relative reduction in
ean platelet aggregation was observed from baseline to
h as measured by LTA, compared with a 90% relative
eduction observed with TEG. By 18 to 24 h, patients
reated with eptifibatide had significant platelet inhibi-
ion compared with baseline (Figs. 6A and 6B). Within 1
onth after procedure 6 patients suffered a recurrent
schemic event, 4 receiving clopidogrel alone and 2
eceiving clopidogrel and eptifibatide. Within 1 year after
rocedure, recurrent ischemic events occurred in 80% of
atients with HPR receiving clopidogrel alone versus
7% of patients with HPR receiving clopidogrel and
ptifibatide. In the NPR group, 11% of patients receiving
lopidogrel alone and 4% of patients receiving both
lopidogrel and eptifibatide suffered recurrent ischemic
vents (Table 6). Although not statistically significant,
his resulted in a 15% relative risk reduction in ischemic
vents 1 month after procedure and a 35% relative risk
eduction in ischemic events 1 year after procedure (p 
.56 and p  0.325, respectively). Bleeding events
ccurred in 1 patient receiving clopidogrel alone (minor)
Figure 4 Cumulative Event Occurrence Over 1 Year
Graph demonstrating cumulative event occurrence over 365 days.
nitial Adverse Events
Table 4 Initial Adverse Events
Total Group (n  100)
Day 0–30 Day 31–36
Ischemic events (n)
Death 0 0
Myocardial infarction 4 1
Target vessel revascularization 0 8
Stroke 0 0
Nontarget vessel revascularization 0 3
Rehospitalization for ischemia 2 5
Total patients with ischemic events, n (%) 6 (6) 17 (17)
Bleeding events (n)
Major bleeding 1 0
Minor bleeding 2 0
Total patients with bleeding events, n (%) 3 (3) 0 (0)
PR  high on-treatment platelet reactivity; NPR  normal on-treatment platelet reactivity.Wnd in 2 patients receiving clopidogrel and eptifibatide
1 major and 1 minor).
iscussion
he current study demonstrates that patients receiving
hronic clopidogrel therapy undergoing nonemergent PCI
ho exhibit high on-treatment preprocedural ADP-
nduced platelet aggregation as measured by LTA (50%
DP-induced aggregation) or TEG (70% ADP-induced
ggregation) are at increased risk for recurrent ischemic
vents. Of 23 patients suffering recurrent ischemic events,
6 patients displayed HPR as measured by LTA, whereas
0 patients displayed HPR as measured by TEG. Moreover,
ean platelet aggregation was significantly higher in pa-
ients suffering recurrent ischemic events than in patients
ithout recurrent events. Of further interest was the obser-
ation that patients not treated with eptifibatide displayed
n 18% increase in mean platelet aggregation from baseline
o 3 h after procedure as measured by LTA. These findings
uggest that selected patients exhibiting preprocedural
latelet inhibition during chronic clopidogrel therapy might
evertheless remain at risk for periprocedural thrombotic
vents due to heightened platelet reactivity to ADP that
ccurs after stenting.
A possible explanation for the absence of an increase in
latelet reactivity to ADP when studied by TEG involves
he use of whole blood as compared with platelet-rich
lasma. Heptinstall et al. (21) have demonstrated the
mportant effects that leukocytes and erythrocytes have on
denine nucleotide metabolism that modify the overall
esponse of platelets to ADP.
Our results are concordant with several previous studies
hat have demonstrated the relationship between insufficient
latelet inhibition, postcoronary stent thrombosis, and isch-
mic cardiovascular events (4,5,10,11). The recent CREST
tudy (Clopidogrel Effect on Platelet Reactivity in Patients
HPR Group (n  22) NPR Group (n  78)
Day 0–30 Day 31–365 Day 0–30 Day 31–365
0 0 0 0
3 1 1 0
0 6 0 2
0 0 0 0
0 2 0 1
2 2 0 3
5 (23) 11 (50) 1 (1) 6 (8)
1 0 0 0
1 0 1 0
2 (10) 0 (0) 1 (1) 0 (0)5ith Stent Thrombosis) demonstrated significantly higher
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ggregation in patients with stent thrombosis as compared
ith patients without stent thrombosis (4), and the PRE-
ARE POST-STENTING (Platelet Reactivity in Patients
nd Recurrent Events Post-Stenting) study reported in-
reased ADP-induced aggregation measured by TEG in
atients suffering ischemic events compared with patients
ithout events (5). Furthermore, Matetzky et al. (10)
eported that patients in the highest quartile of ADP-
nduced aggregation who were stented for acute ST-
egment elevation myocardial infarction had a 40% likeli-
ood for a recurrent cardiovascular event within 6 months.
similar study by Barragan et al. (11) showed high P2Y12
eceptor reactivity as measured by vasodilator-stimulated
hosphoprotein (VASP) phosphorylation levels in patients
ith stent thrombosis. Each of these studies supports the
Figure 5 Combined Receiver-Operator Curve for LTA and TEG
Combined receiver-operating characteristic curve for 5-mol/l ADP-induced LTA
and 2-mol/l ADP-induced TEG at baseline. An area of 0.862 and an area
of 0.881 were observed below the curves of LTA and TEG, respectively, with
p  0.0001 for both areas. AUC  area under the curve; other abbrevia-
tions as in Figure 3.
Prognostic Significance of Selected Variables foIschemic Events According to Multivariate Cox
Table 5 Prognostic Significance of SelectedIschemic Events According to Mult
LTA
p Value Odds Rat
HPR (LTA) 0.001 34.6 (8
HPR (TEG) —
Age (yrs) 0.407 1.0 (0
Presentation* 0.713 1.36 (0
Diabetes 0.810 0.6 (0
Hypertension 0.134 4.9 (0
Smoking (current) 0.978 1.0 (0
BMS 0.725 0.8 (0
*48 h after ACS.
ACS  acute coronary syndrome; BMS  bare-metal stents; CI  confiden
transmittance aggregometry; TEG  thrombelastography.otion that inadequate platelet inhibition, the occurrence of
tent thrombosis, and recurrent ischemic events are signif-
cantly related.
This study is the first to correlate the occurrence of
schemic events with platelet reactivity to ADP in patients
eceiving chronic clopidogrel therapy undergoing non-
mergent PCI. There is currently no existing standard of
reatment for clopidogrel loading in these patients. The
ossibility of further inhibiting platelet reactivity in patients
eceiving chronic clopidogrel therapy with an additional
00-mg loading dose was demonstrated by Kastrati et al. (22),
uggesting routine reloading with clopidogrel in all patients
ndergoing PCI regardless of ongoing clopidogrel treat-
ent. In addition, Kastrati (22) has also suggested increas-
ng the current clopidogrel maintenance dose to 150 mg qd
o further inhibit ADP-induced aggregation. Moreover, our
urrent study demonstrated that the administration of
ptifibatide reduced periprocedural elevation in platelet
eactivity measured by LTA. Because further platelet inhi-
ition is attainable in patients receiving chronic clopidogrel
herapy, and a reduction in platelet reactivity is associated
ith a decrease in ischemic complications, an additional
oading dose of clopidogrel (300 mg or 600 mg), the use of
GP IIb/IIIa inhibitor or an increase in maintenance dose
herapy to 150 mg qd are all therapeutic considerations for
atients receiving chronic therapy undergoing non-
mergent PCI.
Thrombelastography was implemented in the current
tudy to assess its reliability as a monitoring tool for
nalyzing the response to antiplatelet therapy. The TEG,
ombined with the PlateletMapping assay, was able to
dentify a subtherapeutic response that highly correlated
ith the more labor intensive method of LTA. Eighty-
even percent of patients encountering recurrent ischemic
vents exhibited HPR that was identified by TEG. These
ndings are concordant with the results of the PREPARE
OST-STENTING study (5). Therefore, this assay
ight affect the delivery of individualized antiplatelet
herapy.
ession Analysis
ables for
te Cox Regression Analysis
TEG
% CI) p Value Odds Ratio (95% CI)
.2) — —
0.001 26.8 (6.7–107.5)
) 0.835 1.0 (0.9–1.0)
) 0.264 0.4 (0.6–2.1)
) 0.561 0.6 (0.2–2.6)
8) 0.405 2.2 (0.3–13.7)
) 0.906 1.1 (0.2–7.6)
) 0.313 0.5 (0.1–2.0)rRegr
Vari
ivaria
io (95
.3–144
—
.9–1.0
.2–7.1
.2–3.1
.6–38.
.1–6.7
.2–3.2ce interval; HPR  high on-treatment platelet reactivity; LTA  light
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hat HPR is associated with increased ischemic events after
CI, the results overall are limited by a small sample size.
herefore, larger randomized clinical trials in this subset of
atients are necessary to confirm our findings. A second
imitation of the study is that patients were not given an
dditional loading dose of clopidogrel. The clinical benefit
f reloading patients already treated with chronic clopi-
ogrel therapy with a further 300- or 600-mg dose remains
Figure 6 A Comparison of Platelet Reactivity With and Without
(A) Graph demonstrating mean 5 mol/l ADP-induced platelet aggregation with and w
coronary intervention (PCI). *p  0.0001 for the change in platelet aggregation in pat
after PCI in patients receiving eptifibatide versus baseline. (B) Graph demonstrating m
TEG at baseline, 3 h and 18 to 24 h after PCI. *p  0.0001 for change in platelet aggr
elation Between Plateletactivity, GP IIb/IIIa Use, and Ischemic Events
Table 6 Relation Between PlateletReactivity, GP IIb/IIIa Use, and Ischemic Events
HPR (n  22) NPR (n  78)
With GP IIb/IIIa Inhibitor, n (%) 4/7 (57) 1/23 (4)
Without GP IIb/IIIa Inhibitor, n (%) 12/15 (80) 6/55 (11)
P  glycoprotein; HPR  high on-treatment platelet reactivity; n  number of patients with ant
schemic event/number of patients in each quadrant; NPR  normal on-treatment platelet
eactivity; %  percentage of patients in each quadrant with an ischemic event.nclear. Moreover, inherent differences within our study
opulation by virtue of their need for repeat PCI could have
mpacted the prevalence of high platelet reactivity. In
ddition, flow cytometric platelet surface P-selectin and
P IIb/IIIa expression were not measured for additional
ndicators of platelet reactivity to ADP. Finally, medica-
ion was not provided and distributed by our study.
herefore, clopidogrel noncompliance might have con-
ributed to pre-PCI high platelet reactivity and could
ave affected long-term outcomes, because no additional
oading dose was administered. However, preprocedural
ompliance to clopidogrel and aspirin was verified by
ursing staff, and postprocedural compliance was assured
hrough repetitive telephone contacts and outpatient
ource documentation.
In conclusion, patients receiving chronic clopidogrel ther-
py undergoing nonemergent PCI, who exhibit high on-
fibatide
eptifibatide measured by LTA at baseline, 3 h and 18 to 24 h after percutaneous
ceiving eptifibatide versus no eptifibatide. †p  0.0004 for platelet aggregation 3 h
mol/l ADP-induced platelet aggregation with and without eptifibatide measured by
in patients receiving eptifibatide versus no eptifibatide. Abbreviations as in Figure 3.Epti
ithout
ients re
ean 2
egationreatment ADP-induced platelet aggregation by LTA or
t
p
a
c
i
c
c
i
i
m
o
t
c
a
p
R
C
5
E
R
1
1
1
1
1
1
1
1
1
1
2
2
2
666 Bliden et al. JACC Vol. 49, No. 6, 2007
Chronic Clopidogrel Therapy and Ischemic Risk February 13, 2007:657–66he TEG point-of-service device, are at increased risk for
ostprocedural ischemic events. Our data support a mech-
nistic link between the platelet physiologic response and
linical outcomes. The results of this study have potential
mplications for clinicians who do not administer additional
lopidogrel (before or after PCI) to patients receiving
hronic clopidogrel therapy. Platelet function testing might
mprove patient outcomes by assessing the risk for recurrent
schemic events and adjusting subsequent antiplatelet treat-
ent. These treatments might include reloading with a dose
f 300 mg or 600 mg of clopidogrel, additional antiplatelet
reatment with a GP IIb/IIIa inhibitor, or an increased
lopidogrel maintenance dose. Future prospective studies
re required to determine the efficacy of these regimens in
atients with HPR.
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